Novo Nordisk trains sights on Roche with "aggressive" hemophilia drug development

With a stated goal of outstripping Roche's Hemlibra, Novo Nordisk has assumed the full risk of a potential hemophilia drug resulting from a collaboration with Genmab.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen

Novo Nordisk has big dreams for its potential hemophilia treatment, Mim8, but its main goal is beating Roche.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading